beprol 7.5 bisoprolol fumarate 7.5mg tablet blister pack
strides pharma science pty ltd - bisoprolol fumarate, quantity: 7.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; calcium hydrogen phosphate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.
beprol 1.25 bisoprolol fumarate 1.25mg tablet blister pack
strides pharma science pty ltd - bisoprolol fumarate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; calcium hydrogen phosphate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.
beprol 3.75 bisoprolol fumarate 3.75mg tablet blister pack
strides pharma science pty ltd - bisoprolol fumarate, quantity: 3.75 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.
kaptan quetiapine (as fumarate) 300 mg film-coated tablet blister pack
strides pharma science pty ltd - quetiapine fumarate -
kaptan quetiapine (as fumarate) 200 mg film-coated tablet blister pack
strides pharma science pty ltd - quetiapine fumarate -
kaptan quetiapine (as fumarate) 100 mg film-coated tablet blister pack
strides pharma science pty ltd - quetiapine fumarate -
kaptan quetiapine (as fumarate) 25 mg film-coated tablet blister pack
strides pharma science pty ltd - quetiapine fumarate -
rispernia risperidone 6mg tablets bottle
strides pharma science pty ltd - risperidone, quantity: 6 mg - tablet, film coated - excipient ingredients: quinoline yellow; maize starch; lactose monohydrate; hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; macrogol 400 - risperidone is indicated for the treatment of schizophrenia and related psychoses. risperidone is indicated for the treatment of behavioural disturbances in dementia. risperidone is indicated for the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.
rispernia risperidone 6mg tablets blister pack
strides pharma science pty ltd - risperidone, quantity: 6 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; quinoline yellow; maize starch; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - risperidone is indicated for the treatment of schizophrenia and related psychoses. risperidone is indicated for the treatment of behavioural disturbances in dementia. risperidone is indicated for the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.
rispernia risperidone 4mg tablets bottle
strides pharma science pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; lactose monohydrate; indigo carmine; quinoline yellow; hypromellose; titanium dioxide; macrogol 400 - risperidone is indicated for the treatment of schizophrenia and related psychoses. risperidone is indicated for the treatment of behavioural disturbances in dementia. risperidone is indicated for the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.